Skip to main content
. Author manuscript; available in PMC: 2021 Aug 25.
Published in final edited form as: ACS Nano. 2020 Jul 24;14(8):9221–9227. doi: 10.1021/acsnano.0c04753

Figure 1.

Figure 1.

Overview of (1) clinical opportunities for nucleic acid nanoparticles (NANP) therapeutics include small interfering RNAs, antisense oligonucleotides, mRNAs, CRISPR ribonucleoproteins, and vaccine vectors; (2) translational barriers that are limiting progress from academia to the clinic to benefit patients; (3) proposed strategy to overcome these translational barriers; and (4) our recommendation of a consortium to help translate NANPs to the clinic.